Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05970094
Other study ID # H-21069570
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 6, 2023
Est. completion date November 20, 2023

Study information

Verified date November 2023
Source University of Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about and test the effect of an acid/base diet, in chronic kidney patients with CKD stage 4 and 5 in an interventional study with a historical control. The hypothesize is, that an acid/base diet will reduce the degree of acidosis and the need for oral bicarbonate supplements.


Description:

Observational studies indicate that diets with a low "potential renal acid load (PRAL)" is associated with a lower serum-bicarbonate value. The aim is to investigate this association with an interventional studydesign. Participants will be asked to follow a restricted diet with a low "PRAL" during a 6 week trial divided in three periodes: two week free living control, two week intervention and a two week free living follow-up. The PRAL calculation tool will be used to create a diet low in acid, based on this the patients will receive individual diet plans. The diet will comply with national treshold guidelines for potassium and protein, this is due to the high risk of hyperkalemia in patients with chronic kidney disease. The patients will be asked to document their food and drink intake by taking pictures of their plates and cups before and after a meal, over a 24 hour period.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 20, 2023
Est. primary completion date August 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Chronic acidosis (plasma-bicarbonat under 22 mmol/l at multiple measures within the last 12 months). - Diagnosed with non-dialysis needed chronic kidney disease in stage 4 and 5 (eGFR below 30 ml/min/1,73 m2) - Of legal age and over 18 of years - Understand danish and understand the written material - Able to cooperate about the diet - Able to take pictures with their phone or willing to learn Exclusion Criteria: - Vegan and vegetarian with very low intake of animal protein (below 25 g/day) - Pregnant or breast feeding - Patients with short bowel syndrome, brickre's bladder, pancreatitis or any other known malabsorption problem - Potassium above 5 mmol/l - Ongoing infection

Study Design


Intervention

Other:
Low PRAL
Two weeks on a low PRAL diet compared to 2 week free living

Locations

Country Name City State
Denmark Nordshjaellands Hospital Hillerød

Sponsors (2)

Lead Sponsor Collaborator
University of Copenhagen Nordsjaellands Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Plasma-Potassium mmol/l 6 weeks
Other Plasma-calcium mmol/l 6 weeks
Other Plasma-magnesium mmol/l 6 weeks
Other Plasma-inorganic phosphorous mmol/l 6 weeks
Primary Plasma-total CO2 mmol/l 6 weeks
Secondary Plasma-alkaline phosphatase U/l 6 weeks
Secondary Plasma-sodium ion mmol/l 6 weeks
Secondary Plasma-creatinine umol/l 6 weeks
Secondary Plasma-parathyroid hormone pmol/l 6 weeks
Secondary Plasma-carbamide mmol/l 6 weeks
Secondary Plasma-albumin g/l 6 weeks
Secondary Urine-phosphorous mmol/d 6 weeks
Secondary Urine-sodium mmol/d 6 weeks
Secondary Urine-potassium mmol/d 6 weeks
Secondary Urine-carbamide mmol/d 6 weeks
Secondary Urine-albumin mg/d 6 weeks
Secondary Urine-magnesium mmol/d 6 weeks
Secondary Urine-creatinine mmol/d 6 weeks
Secondary Uirne-calcium mmol/d 6 weeks
Secondary Total acid excretion in urine meqv/day 6 weeks
Secondary Urine-pH Units 6 weeks
Secondary Urine NH4+ excretion mmol/day 6 weeks
Secondary Urine net acid excretion meqv/day 6 weeks
Secondary Urine bicarbonate mmol/l 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03545113 - Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease N/A
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT04559321 - Holmium Vs Trilogy Kidney Stones GUY's 1-2 Phase 3
Recruiting NCT05036850 - China Kidney Patient Trials Network
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Completed NCT01679587 - Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD) Phase 1
Completed NCT01155141 - Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH Phase 4
Completed NCT00755690 - Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Completed NCT03213158 - Ixazomib for Desensitization Phase 2
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting NCT06067867 - Kidney and Pregnancy Registry
Recruiting NCT04110080 - Enhanced Recovery After Surgery in Kidney Transplant Donors N/A
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Enrolling by invitation NCT05324878 - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Completed NCT03394859 - Electronic Medical Records and Genomics (eMERGE) Phase III